TrialNature communications2026

Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial.

Jiayu Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.